

PRESS RELEASE

Indoco's Q1FY20 revenues grow at 16%

Mumbai, 13th August 2019: Indoco Remedies posted revenues of ₹ 247.2 crores during the First quarter of FY 2019-20, as against ₹ 212.5 crores, for the same quarter last year. For the quarter, the Company posted a profit of ₹ 2.2 crores, as against loss of ₹ 12.0 crores, same quarter last year.

Commenting on the first quarter results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, "The Company's India Business is witnessing a progressive trend, as reflected in the Secondary Sales data as per AWACS and in Prescription (Rx) generation as per SMSRC. With the regulatory challenges easing out, the international business is also poised for a higher growth".

For the quarter ended June'19, the standalone financials are as under:

(₹ in Crores)

Particulars	Apr'19 - June'19	Apr'18 - June'18
Net Revenues	247.2	212.5
EBIDTA	22.75	11.57
Operating Profit	10.76	0.88
Profit After Tax	2.2	(12.0)
EPS (Face value ₹ 2/-) (Not annualized)	0.24	(1.30)

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 140 million Company, employs over 6000 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around 3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensiform, Sensodent-KF, Karvol Plus, Glychek, Kidodent, Carmicide, Bactogard, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com / corpcom@indoco.com